Molsidomina WZF

Molsidomina WZF Uses, Dosage, Side Effects, Food Interaction and all others data.

Molsidomina WZF is an orally active, long-acting vasodilator, which belongs to the class of medications known as syndnones. Interestingly, it is being studied as being a preventive measure in cerebral infarction .

Molsidomina WZF leads to smooth muscle relaxation in the coronary blood vessels, relieving symptoms of angina and increasing blood flow to the coronary arteries.

Molsidomina WZF
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Molsidomina WZF
Generic	Molsidomine
Molsidomine Other Names	Molsidomina, Molsidomine, Molsidominum
Type
Formula	C₉H₁₄N₄O₄
Weight	Average: 242.235 Monoisotopic: 242.101504947
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	Lithuania, Poland
Last Updated:	September 19, 2023 at 7:00 am

Uses

Molsidomina WZF is a long-acting vasodilator used to treat angina pectoris, including in association with left heart failure and acute myocardial infarction.

The indications for use of molsidomine include ischemic heart disease, angina, chronic heart failure, and pulmonary hypertension .

Molsidomina WZF is also used to associated treatment for these conditions: Angina Pectoris, Chronic Stable Angina Pectoris, Unstable Angina Pectoris

How Molsidomina WZF works

Molsidomina WZF, a cardiovascular drug, acts in a similar fashion to organic nitrates. The SIN-1A metabolite of molsidomine has a pharmacologically active group of nitric oxide, which increases levels of cyclic GMP, and decreases intracellular calcium ions in smooth muscle cells. This leads to relaxation of smooth muscle in the blood vessels, and inhibits platelet aggregation.

Volume of Distribution

98 L

Elimination Route

Peak plasma drug concentration (tmax) occurs from 1 to 2 hours after administration.

Clearance

renal excretion is the main route of elimination of the metabolites in humans (90% to 95%) About 2% of the ingested drug is excreted unchanged in the urine.